Equities
Health CareMedical Equipment and Services
  • Price (HKD)0.82
  • Today's Change-2.34 / -74.05%
  • Shares traded12.88m
  • 1 Year change-83.43%
  • Beta1.0000
Data delayed at least 15 minutes, as of Feb 23 2026 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Microport Cardioflow Medtech Corp is a medical device company primarily engaged in the provision of total solutions to physicians and patients for the treatment of structural heart diseases. The Company’s main business is engaged in the research and development and commercialization of transcatheter and surgical solutions for structural heart diseases. The Company’s pipelines include transcatheter aortic heart valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) product, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products and procedural accessories. The Company conducts its business in the domestic and overseas markets.

  • Revenue in HKD (TTM)417.67m
  • Net income in HKD5.51m
  • Incorporated2019
  • Employees417.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
OrbusNeich Medical Group Holdings Ltd1.32bn318.11m2.95bn1.43k9.230.92188.122.230.38570.38571.603.860.39190.93254.20991,491.509.487.5910.299.0267.9168.6124.1916.079.95--0.010710.026.6511.24-11.8841.6829.71--
MicroTech Medical (Hangzhou) Co Ltd500.85m-31.45m3.14bn645.00--1.42--6.27-0.0754-0.07541.205.310.20153.654.02738,722.20-1.27-4.48-1.38-4.7048.6548.32-6.28-39.298.33--0.0154--36.4846.1349.51--22.22--
Jenscare Scientific Co Ltd15.26m-278.21m3.34bn174.00--3.37--218.73-0.6824-0.68240.03752.370.01250.0508--72,310.27-23.35---24.76--88.09---1,864.69--6.39-854.860.0631------52.25------
Guanze Medical Infrm Indstry (Hldng) Ltd167.69m23.56m3.42bn58.00145.7211.43103.8720.390.02470.02470.17720.3150.50732.211.302,942,011.007.239.508.3312.0436.7941.4314.2513.095.2351.530.054434.79-0.21272.03-37.59-5.0824.24--
Acotec Scientific Holdings Ltd673.73m114.66m3.62bn645.0030.712.2120.735.370.37610.37612.245.230.33531.063.531,036,500.005.710.24676.450.28975.2381.3317.020.71225.57--0.14060.0012.6933.72260.8817.7483.44--
Peijia Medical Ltd758.74m-255.90m3.80bn1.04k--1.69--5.00-0.3868-0.38681.143.340.25611.4017.04724,676.90-8.76-26.57-10.02-28.9969.2571.23-34.21-247.651.49-15.300.1396--39.53101.1342.28--83.33--
MicroPort CardioFlow Medtech Corp417.67m5.51m4.02bn417.00267.120.614837.249.630.01180.01180.89655.140.14231.001.77971,315.000.0886-13.380.0996-16.8469.0864.410.6228-124.496.50--0.112--7.5475.8589.51--26.60--
Modern Dental Group Ltd3.50bn478.00m5.24bn8.59k11.001.768.381.500.50930.50933.733.190.82979.044.89492,119.5011.428.0813.349.6054.0651.8513.7610.322.7654.800.199940.786.056.990.965120.360.4449--
Lepu Scientch Mdcl Tchnlgy Shnghi Co Ltd627.58m326.55m5.45bn374.0016.682.4315.178.680.94180.94181.816.470.24940.83236.061,998,669.0012.987.8314.899.2887.2389.1852.0335.625.03--0.000681.7844.4032.2862.2236.4582.59--
BrainAurora Medical Technology Ltd193.73m-239.01m5.58bn174.00--18.50--28.82-0.1888-0.18880.1530.22210.3274--1.241,218,427.00-40.54---112.29--41.26---123.83-----10.130.6324--82.01--44.78------
Yidu Tech Inc845.08m-101.08m5.86bn823.00--1.35--6.93-0.0957-0.09570.79894.140.159524.781.341,026,825.00-2.03-24.00-2.38-30.0834.4135.64-12.72-123.004.37--0.0321---11.415.0839.58--26.45--
MicroPort NeuroScientific Corp836.93m231.36m5.98bn522.0025.933.0420.117.150.40070.40071.453.410.35431.293.101,588,098.009.696.0411.237.0173.5874.5827.3616.604.71142.060.014135.6914.4432.9074.6340.172.49--
Data as of Feb 23 2026. Currency figures normalised to Microport Cardioflow Medtech Corp's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

8.57%Per cent of shares held by top holders
HolderShares% Held
HHLR Advisors Ltd.as of 19 Dec 2025538.50m8.46%
Dimensional Fund Advisors LPas of 30 Nov 20255.70m0.09%
SSgA Funds Management, Inc.as of 05 Feb 2026624.00k0.01%
Dimensional Fund Advisors Ltd.as of 30 Nov 2025530.78k0.01%
American Century Investment Management, Inc.as of 31 Dec 202545.00k0.00%
Invesco Hong Kong Ltd.as of 30 Jan 202640.63k0.00%
DFA Australia Ltd.as of 30 Nov 20256.50k0.00%
Storebrand Asset Management ASas of 31 Jan 2026799.000.00%
Norges Bank Investment Managementas of 30 Jun 2025469.000.00%
BOCI-Prudential Asset Management Ltd.as of 30 Sep 202520.000.00%
More ▼
Data from 31 Dec 2025 - 26 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.